TimesSquare Capital Management LLC Buys 640,329 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

TimesSquare Capital Management LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 250.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 895,574 shares of the company’s stock after buying an additional 640,329 shares during the quarter. TimesSquare Capital Management LLC owned about 0.97% of NewAmsterdam Pharma worth $23,016,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after buying an additional 1,399 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $80,000. Quarry LP lifted its position in shares of NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares during the last quarter. Finally, Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the third quarter worth $128,000. 89.89% of the stock is currently owned by institutional investors.

Insider Activity

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29. Following the transaction, the insider now owns 11,150,461 shares in the company, valued at $283,110,204.79. The trade was a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 404,927 shares of company stock worth $10,390,787. Company insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $19.12 on Thursday. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The stock’s fifty day moving average price is $23.42 and its 200-day moving average price is $20.17.

Wall Street Analyst Weigh In

NAMS has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank lifted their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $41.60.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.